These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 19360352)
41. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546 [TBL] [Abstract][Full Text] [Related]
42. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma. Chen L; Zhao Y; Halliday GC; Berry P; Rousseau RF; Middleton SA; Nichols GL; Del Bello F; Piergentili A; Newell DR; Lunec J; Tweddle DA Br J Cancer; 2014 Aug; 111(4):716-25. PubMed ID: 24921920 [TBL] [Abstract][Full Text] [Related]
43. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Thompson T; Andreeff M; Studzinski GP; Vassilev LT Mol Cancer Ther; 2010 May; 9(5):1158-68. PubMed ID: 20406950 [TBL] [Abstract][Full Text] [Related]
44. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622 [TBL] [Abstract][Full Text] [Related]
45. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma. Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809 [TBL] [Abstract][Full Text] [Related]
46. Ribosomal proteins L11 and L5 activate TAp73 by overcoming MDM2 inhibition. Zhou X; Hao Q; Zhang Q; Liao JM; Ke JW; Liao P; Cao B; Lu H Cell Death Differ; 2015 May; 22(5):755-66. PubMed ID: 25301064 [TBL] [Abstract][Full Text] [Related]
48. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis. Cipriano R; Patton JT; Mayo LD; Jackson MW Cell Cycle; 2010 Apr; 9(7):1373-9. PubMed ID: 20305378 [TBL] [Abstract][Full Text] [Related]
49. Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules. Leão M; Gomes S; Bessa C; Soares J; Raimundo L; Monti P; Fronza G; Pereira C; Saraiva L Exp Cell Res; 2015 Jan; 330(1):164-77. PubMed ID: 25265062 [TBL] [Abstract][Full Text] [Related]
50. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents. Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102 [TBL] [Abstract][Full Text] [Related]
51. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Saha MN; Jiang H; Mukai A; Chang H Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913 [TBL] [Abstract][Full Text] [Related]
52. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2. Liu T; Xiong J; Yi S; Zhang H; Zhou S; Gu L; Zhou M Oncogene; 2017 Mar; 36(12):1678-1686. PubMed ID: 27617579 [TBL] [Abstract][Full Text] [Related]
53. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Secchiero P; Zerbinati C; Melloni E; Milani D; Campioni D; Fadda R; Tiribelli M; Zauli G Neoplasia; 2007 Oct; 9(10):853-61. PubMed ID: 17971905 [TBL] [Abstract][Full Text] [Related]
54. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964 [TBL] [Abstract][Full Text] [Related]
55. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity. Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917 [TBL] [Abstract][Full Text] [Related]
56. MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells. Ghassemifar S; Mendrysa SM Neurosci Lett; 2012 Mar; 513(1):106-10. PubMed ID: 22343310 [TBL] [Abstract][Full Text] [Related]
57. MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation. Sarisozen C; Tan Y; Liu J; Bilir C; Shen L; Filipczak N; Porter TM; Torchilin VP J Drug Target; 2019; 27(5-6):624-633. PubMed ID: 30656973 [TBL] [Abstract][Full Text] [Related]
58. Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis. Bhattacharya S; Ray RM; Chaum E; Johnson DA; Johnson LR Invest Ophthalmol Vis Sci; 2011 May; 52(6):3368-80. PubMed ID: 21345989 [TBL] [Abstract][Full Text] [Related]
59. Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells. Czaplinski S; Abhari BA; Torkov A; Seggewiß D; Hugle M; Fulda S Oncotarget; 2015 Dec; 6(39):41522-34. PubMed ID: 26575016 [TBL] [Abstract][Full Text] [Related]
60. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Gu L; Zhu N; Findley HW; Zhou M Leukemia; 2008 Apr; 22(4):730-9. PubMed ID: 18273046 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]